BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 11, 2023
Home » Topics » Merger, BioWorld MedTech

Merger, BioWorld MedTech
Merger, BioWorld MedTech RSS Feed RSS

Japan Medical Device Technologys resorbable coronary stent

Kaneka buys Japan Medical Tech to expand coronary stents business

Dec. 11, 2023
By Tamra Sami
No Comments

Kaneka Corp. has acquired Japan Medical Device Technology Co. Ltd. (JMDT), to expand its reach in the coronary stent business segment. Financial terms of the deal were not disclosed.


Read More
eopatch2.jpg

Medtronic scraps plans to buy wearable insulin patch maker Eoflow

Dec. 7, 2023
By Marian (YoonJee) Chu
No Comments
One of the largest med-tech deals of 2023 was wiped off the charts when Medtronic plc terminated a $738 million agreement to acquire South Korean wearable insulin patch maker Eoflow Co. Ltd., citing “multiple breaches” under its agreements, on Dec. 6.
Read More
VYRSA

Joint venture: Nevro acquires Vyrsa for up to $75M

Dec. 1, 2023
By Annette Boyle
No Comments
Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 million at closing and agreed to up to $35 million in additional payments contingent on the achievement of certain development and sales milestones.
Read More
Broncus Archimedes Navigation System

Broncus acquires Chinese pulmonary device company Hangzhou Jiangliang

Dec. 1, 2023
By Tamra Sami
No Comments
Broncus Holding Corp. subsidiary Broncus Hangzhou is acquiring Chinese medical device company Hangzhou Jingliang in the form of an equity transfer agreement for ¥5.4 million (US$758,000). The move will strengthen Broncus’ R&D capabilities in the flexible robotic space and will allow the company to offer pulmonology diagnostics and therapeutic solutions covering the complete product life cycle.
Read More
Heart with blocked arteries

J&J surprises with $400M Laminar acquisition

Nov. 30, 2023
By Annette Boyle
No Comments

Johnson & Johnson completed the previously unheralded acquisition of privately held Laminar Inc. for $400 million upfront, with undisclosed contingent payments depending on achievement of clinical and regulatory milestones starting in 2024. The deal provides the med-tech giant a potentially game-changing entree into the lucrative left atrial appendage (LAA) market.


Read More
3D illustration of Agili-C in knee joint

Smith+Nephew steps up with $330M acquisition of Cartiheal

Nov. 27, 2023
By Annette Boyle
No Comments
Smith+Nephew plc struck a deal to acquire Cartiheal Ltd. for $180 million at closing and $150 million in contingent payments, seven months after Bioventus Inc. backed out of its agreement to buy the developer of the Agili-C cartilage regeneration platform for $450 million.
Read More
Acutus Acqmap

Acutus torches ablation business to focus on manufacturing

Nov. 9, 2023
By Annette Boyle
No Comments
Acutus Medical Inc. revealed plans after the Nasdaq closing bell on Nov. 8 to abandon the electrophysiology business as part of a massive restructuring that will leave the company entirely committed to manufacturing and distribution of Medtronic plc’s left-heart access products. The shift will put 65% of Acutus employees out of work and leaves the future of its cardiac ablation and mapping products up in the air.
Read More

Elekta buys Icad’s brachytherapy business for $5.5M

Nov. 8, 2023
By Shani Alexander
No Comments
The acquisition of Icad Inc.’s brachytherapy business by Elekta AB takes the company a step closer to achieving its goal of providing hope to the millions of people dealing with cancer, John Lapré, president of Elekta’s Brachy and Neuro Solutions unit, told BioWorld. Elekta paid approximately $5.5 million for Icad’s subsidiary Xoft. In addition, most of Xoft’s staff and its main facility in San José, Calif., was transferred to the company.
Read More
Stock chart, red down arrow
Med-tech financings October 2023

Up from September low, med-tech financings down nearly 42% for the year

Nov. 3, 2023
By Amanda Lanier
No Comments
Med-tech saw some good news in October, with total financings value reaching $1.22 billion, an increase of 89.23% from the $645.75 million in September. However, the increase didn’t make up for the broader year-over-year decline in med-tech investments.
Read More
AI dollar sign

Ametek treats shareholders with $1.9B Paragon acquisition

Oct. 31, 2023
By Annette Boyle
No Comments

There’s nothing scary for Ametek Inc. shareholders in the $1.9 billion acquisition of Paragon Medical Inc. announced on Oct. 31, 2023. The deal moves the industrial technology company solidly into the med-tech space as it picks up Paragon’s portfolio of products in orthopedics, minimally invasive surgery, robotic surgery and drug delivery, and adds an estimated $500 million per year in revenue and “very strong EPS accretion,” Ametek CEO David Zapico said in an investor call on Oct. 31.


Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 11, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 11, 2023.
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing